Neurothera Labs (FRA:C0A) PB Ratio: (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C0A Neurothera Labs Inc FRA:C0A
32 GF Score
Price €0.15
! 2 Warning Signs
View Full Analysis

What is Neurothera Labs PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-12), Neurothera Labs's share price is €0.149. Neurothera Labs's Book Value per Share for the quarter that ended in Dec. 2025 was €0.00. Hence, Neurothera Labs's PB Ratio of today is .

The historical rank and industry rank for Neurothera Labs's PB Ratio or its related term are showing as below:

FRA:C0A' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 172.84
Current: 172.84

During the past 5 years, Neurothera Labs's highest PB Ratio was 172.84. The lowest was 0.00. And the median was 0.00.

FRA:C0A's PB Ratio is ranked worse than
99.78% of 920 companies
in the Drug Manufacturers industry
Industry Median: 1.98 vs FRA:C0A: 172.84

During the past 12 months, Neurothera Labs's average Book Value Per Share Growth Rate was -21.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -11.70% per year.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Neurothera Labs was 30.90% per year. The lowest was -11.70% per year. And the median was 9.60% per year.

Back to Basics: PB Ratio


Neurothera Labs  (FRA:C0A) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Neurothera Labs PB Ratio Related Terms


Neurothera Labs PB Ratio Historical Data

* Premium members only.

The historical data trend for Neurothera Labs's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs PB Ratio Chart

Neurothera Labs Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
PB Ratio
0.00 0.00 0.00 0.00 0.00

Neurothera Labs Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Dec25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:C0A vs LLY, JNJ, ABBV: PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Neurothera Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurothera Labs PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's PB Ratio distribution charts can be found below:

* The bar in red indicates where Neurothera Labs's PB Ratio falls into.


FRA:C0A
32GF Score
Neurothera Labs Inc FRA:C0A
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurothera Labs PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Neurothera Labs's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=0.149/0.001
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Neurothera Labs Business Description

Other Exchanges NTLX:Canada
Address 325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
32GF Score

Get the complete analysis for FRA:C0A

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price